GlassScriptPhysician profile
Doreen L Johnson
NPI 1194883199
$844.90
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $451.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.68 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $112.40 | 2021 | |
| Genzyme Corporation | $95.66 | 2022 | |
| Pfizer INC. | $67.19 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $63.41 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $56.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.04 | 2021-2022 | |
| Amgen INC. | $25.10 | 2021 | |
| Biofrontera INC. | $24.65 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.81 | 2022 | |
| Galderma Laboratories, L.P. | $21.69 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doreen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.